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Abstract
Recent meta-analyses have created uncertainties regarding the appropriate clinical role of
colloid resuscitation fluids in critically ill patients and prompted changes in fluid management
practice. Such changes may not be justified in view of methodological limitations inherent in
the meta-analyses. Further research is nevertheless needed to resolve the questions raised
concerning the relationship between choice of resuscitation fluid and patient outcome.
Animal studies can play an important part by reliably indicating whether particular fluids are
likely to prove effective and safe in clinical trials. It is important to avoid costly large-scale
clinical trials that fail to demonstrate the clinical utility of the tested therapy, as resources
expended in failed trials raise overall development costs and thereby restrict the range of
therapies meeting criteria of commercial feasibility. Promising therapies may thus not be
pursued, even though an urgent clinical need may exist. An alternative pathway of preclinical
research may be of value in avoiding some of the major clinical trial failures of recent years,
particularly in the area of sepsis. This alternative pathway commences with the formulation of
hypotheses by therapeutics developers. Independent preclinical investigators are
challenged, by means of a competitive request for proposals, to test the hypotheses in
rigorous randomized studies employing clinically relevant animal models. Promising
proposals would then be selected for further development with the aid of peer review. The
results of the randomized animal studies, along with other preclinical data, could also be
evaluated using accepted principles of ‘critical appraisal’ commonly applied to clinical trial
results. This critical appraisal might, where appropriate, include meta-analysis of animal study
findings. This alternative preclinical pathway to new product evaluation should be completed
before the commencement of large-scale clinical trials.
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Introduction
Recent meta-analyses have raised fundamental questions
regarding optimal fluid management in critically ill patients.
A meta-analysis of randomized, controlled trials comparing
colloid with crystalloid administration with respect to mor-
tality did not support continued use of colloids for volume
replacement in such patients [1]. Among randomized trials
comparing albumin administration with either crystalloid orhttp://ccforum.com/content/4/S2/S8
no albumin, a second meta-analysis suggested higher
mortality in albumin recipients [2]. Numerous concerns
have been voiced regarding the methodological sound-
ness of these meta-analyses. Indeed, a subsequent meta-
analysis failed to confirm an increased mortality risk with
colloids [3]. Usage of albumin for fluid replacement has
nevertheless declined in the wake of these reports [4].
Substitution of artificial colloid for albumin may have
accounted for some of this decline.
One limitation of the meta-analyses was inclusion of
numerous randomized trials from the late 1970s and early
1980s that may not have accurately reflected current
practice. Most of the randomized trials analyzed were, in
addition, unblinded, so the possibility of systematic bias
cannot be dismissed. It should also be emphasized that
meta-analyses with such limitations can be viewed as
useful for generating hypotheses rather than supporting
evidence-based clinical recommendations [3]. Notwith-
standing their limitations, however, the meta-analyses have
exerted an impact on clinical practice. Further randomized
trials are now, arguably, needed to clarify the clinical utility
of colloids, such as albumin. The foundation for such ran-
domized trials should, furthermore, be laid by conducting
appropriate preclinical research.
Underscoring the importance of appropriate rigorous pre-
clinical research are the instructive cases of experimental
sepsis therapy with monoclonal antibodies (mAb) against
tumour necrosis factor (TNF) or endotoxin. These
approaches appeared to embody sound therapeutic prin-
ciples; namely, neutralizing key mediators of sepsis. The
animal models employed to evaluate these therapies did
not, unfortunately, adequately mimic clinical sepsis [5–7].
The principal preclinical study providing a basis for subse-
quent clinical trials of anti-TNF mAb therapy involved a
baboon bacteraemia model. Baboons received a lethal
dose of Escherichia coli, and control animals developed
rapid-onset shock and organ failure, succumbing within
7 h of bacterial challenge. The model was thus based pri-
marily upon intoxication as the relevant pathological
process rather than infection, which is more characteristic
of clinical sepsis. Subsequent randomized clinical trials
failed to demonstrate a survival benefit of anti-TNF mAb
therapy [8,9].
The seminal animal study of anti-endotoxin therapy with
mAb HA-1A involved, unlike clinical sepsis, pretreatment
with the therapeutic agent and neither volume resuscita-
tion nor adjuvant antibiotic therapy [10]. The preclinical
evidence was nevertheless judged adequate to justify the
initiation of clinical trials. In a double-blind, randomized
clinical trial of 543 sepsis patients, no overall difference in
survival could be demonstrated, although post hoc sub-
group analysis suggested mortality reduction in patients
with gram-negative bacteraemia receiving HA-1A [11]. A
second, larger-scale, double-blind, randomized clinical trial
was commenced. Prior to publication of its results,
however, findings were reported from a randomized study
in a canine model of gram-negative septic shock [12]. The
canine model was clinically relevant by the criteria that the
animals received aggressive fluid resuscitation as well as
antibiotics and that HA-1A was administered subsequent
to bacterial challenge; in this model, HA-1A actually
decreased survival. The larger-scale clinical trial was
reported thereafter. This larger trial, which involved 2199
patients and 603 investigators at 513 community and uni-
versity-affiliated hospitals in the United States, failed to
provide evidence supporting the use of HA-1A for treat-
ment of sepsis [13].
The costly and disappointing failed sepsis clinical trials
suggest that there may be more risk-averse and cost-
effective approaches to be taken in the overall process of
preclinical and clinical research by which therapeutics are
evaluated. A proposal is presented in this paper that could
reduce the overall risks and attendant costs of developing
therapeutics for the critical care environment. The pro-
posal calls for an alternative to the conventional pathway
for preclinical research (Figure 1). First, developers of
therapeutics should assume a leadership role in articulat-
ing hypotheses and challenging independent preclinical
investigators to design and conduct rigorous randomized
studies addressing the hypotheses in animal models that,
as faithfully as possible, reproduce the clinical condition of
interest. All available preclinical data, including the results
of the randomized animal trials, should then be subjected
to standard ‘critical appraisal’, which might include meta-
analysis of the available animal studies as appropriate. Ini-
tiation of large-scale clinical trials should await the
completion of this analysis.
Elements of an alternative pathway
Animal studies can serve an array of purposes and have
conventionally been employed to evaluate the pharmacol-
ogy, toxicology and mechanisms of action for therapeutics,
as well as providing insights into in vivo efficacy and
safety (Figure 1). Studies of this type will always continue
to play a role in therapeutics development. Animal model
studies can and should nevertheless also be designed to
yield reliable data addressing specific hypotheses regard-
ing clinical utility for particular indications. The design of
animal studies may unfortunately be driven by the research
interests of independent preclinical investigators, often
using previously established animal models that may not
be adequately tailored to mimic accurately a clinical condi-
tion of interest. Insufficient emphasis is thus placed on rig-
orous testing of hypotheses related to clinical utility in this
approach. An undesirable byproduct of primarily investiga-
tor-driven research is lack of adequate data in the litera-
ture bearing on the clinical potential of therapies under
development. This byproduct problem could be rectified,Critical Care    Vol 4 No S2 Sibbald
at least in part, by greater exercise of leadership on the
part of therapeutics developers.
These developers should take the responsibility to enunci-
ate the explicit hypotheses that would need to be
addressed in determining the worthiness of therapeutics
to advance into clinical trials. Therapeutics developers
should challenge independent preclinical investigators to
design and conduct animal studies that rigorously test
these hypotheses, in clinically relevant models. The familiar
and well-established ‘request for proposals’ (RFP) could
be used to implement this approach. The RFP would
clearly specify the hypotheses to be tested, and would
typically appear in medical journals and stipulate a specific
time period during which competitive proposals respon-
sive to the RFP might be submitted. Competition in
addressing a clearly defined and clinically relevant goal
can be expected to elicit the full creativity and resourceful-
ness of interested preclinical investigators in identifying or
devising suitable animal models and designing appropri-
ate studies. This competitive process is likely to culminate
in high-quality research proposals. The selection of the
best proposals for funding might then be accomplished
via peer review, using an advisory panel of experts in the
field. The RFP might also allow investigators to propose
additional research programme components addressing
topics of interest such as mechanisms of action. The
needs of the therapeutics developer and the research
interests of the independent preclinical investigator might
thus be simultaneously accommodated.
A major advantage of this hypothesis-driven competitive
research approach is that preclinical investigators will be
challenged both to formulate imaginative and sound pro-
posals and, as necessary, to develop improved or novel
animal models to replicate the clinical condition of interest.
Collaboration with veterinarians may be of value in this
regard. Ongoing research makes it clear that animal
models can be improved and that novel models can arise,
in some instances with the aid of emerging technology.
Recently, for example, an improved clinically relevant
sepsis model in the conscious rat has been described [7].
Creation of interleukin-10-deficient knockout mice by
genetic engineering has additionally provided a new
Figure 1
Conventional and proposed alternative pathway for preclinical research, and costs associated with various phases in the development of
therapeutics based on the estimates of Drews and Ryser [16].
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Phase IIImodel of intestinal inflammation [14]. It should also be fea-
sible, with the collaboration of veterinarians, to identify
models representative of other clinical conditions such as
haemorrhagic shock or reperfusion injury.
Critical appraisal of animal model studies
All available preclinical data, including those generated by
the randomized animal model studies, should be sub-
jected to critical appraisal before large-scale clinical trials
commence. An approach for critically appraising animal
model studies of sepsis has been delineated [15]. This
approach is summarized in Table 1 and calls for both the
condition of interest, such as sepsis, and the therapeutic
intervention to be defined, and proceeds to address a
series of key questions. Are the study results valid? Was
the study blinded? Was it randomized? What were the
results? Were the data subjected to appropriate statistical
analysis? Was the study adequately statistically powered
to answer the questions being posed? What is the rele-
vance of the animal data to the design and anticipated
results of future human studies? Finally, the strength and
quality of all the available preclinical evidence need to be
taken into account as a basis for recommendations
regarding clinical trials to be undertaken.
This type of critical appraisal should be routinely incorpo-
rated in the preclinical evaluation of therapeutic modalities,
including resuscitation fluids. One obvious benefit would
be to avoid misallocation of resources to support unfruitful
clinical trials. In this regard, all participants in the health-
care system have a stake in seeing that only clearly
promising clinical trials are conducted, since the costs of
failed trials will ultimately be born by the overall healthcare
system and not solely by the developers of therapies. All
participants would, furthermore, benefit from lowering the
overall costs associated with developing therapeutics, cur-
rently estimated at US$500 million [16]. This very high
typical development cost sharply restricts the range of
therapeutics that meet the criteria for commercial feasibil-
ity based on standard discounted cash flow rate of return
financial models [16]. Numerous promising therapeutics
remain undeveloped, notwithstanding clinical need. Rigor-
ous animal studies in clinically relevant models in conjunc-
tion with critical appraisal of all available preclinical
evidence might, at modest incremental cost, avoid the
massive waste of resources entailed in failed large-scale
clinical trials and thus contribute to lower overall develop-
ment costs for therapeutics.
Meta-analysis of animal studies
One of the important tools for critical appraisal is meta-
analysis, which emerged in the 1990s as a major
approach for fully capitalizing on the wealth of data gener-
ated by clinical trials, especially those of relatively small
scale. Meta-analysis is a quantitative form of systematic
review employing statistical methods to combine and
summarize the results of multiple studies [17]. The
methodology of meta-analysis is presented in Table 2.
Meta-analyses, typically applied to the results of random-
ized clinical trials, also increasingly address the findings of
observational clinical studies [18]. Preclinical data, fre-
quently derived from numerous small-scale animal studies,
would also be an appropriate subject for meta-analysis,
which might reveal overall trends not evident in small
studies affording, individually, only limited statistical power
and yielding, collectively, sometimes apparently inconsis-
tent results.
Although animal data have been much less frequently sub-
jected to meta-analysis than clinical data, the feasibility of
animal study meta-analysis has been demonstrated in a
variety of investigations. For instance, meta-analysis has
been reported of rodent studies on dietary fat intake in
relation to the occurrence of mammary tumours [19,20].
Meta-analytic approaches to animal carcinogenicity experi-
ments have also been described [21,22]. Two meta-ana-
lytic investigations have encompassed both animal and
human data. In one, separate meta-analyses of 41 rat
studies and 17 clinical trials each revealed a significant
association between proteinuria and glomerulosclerosis
[23]. In the other investigation, separate meta-analyses of
four rat and five human studies were conducted to model
the relationship between arterial blood toluene levels and
behavioural responses [24]. Interestingly, in a meta-
analysis on the accuracy of dimercaptosuccinic acid
http://ccforum.com/content/4/S2/S8
Table 1
Critical appraisal of animal model studies
Study selection
Indication (eg sepsis)
Category
Pathophysiology
Therapy
Other
Study assessment
Validity of results
Randomization
Accounting for all experimental subjects
Blinding
Comparability of groups at baseline
Lack of confounders
Specific findings
Effect size
Precision
Generalizability to corresponding clinical indication
Clinical relevance of animal model
Supportive therapies similar to those in the clinical setting
Consideration of intercurrent illness
Species specificity of the model
Potential cost-effectiveness
Evidence-based recommendations
Strength of evidence
Quality of evidencescintigraphy for the diagnosis of acute pyelonephritis, it
was necessary to focus on animal studies because
nephrectomy for histological examination in patients is
considered unethical [25].
Animal study meta-analyses to date have underscored the
importance of key methodological issues that are also rou-
tinely addressed in meta-analyses of human trials. Meta-
analyses of animal data have thus included consideration
of between-study heterogeneity [26], sensitivity analyses
as appropriate [27] and evaluation of included study
quality [28].
There are clearly no conceptual barriers to meta-analysis
of animal data. Meta-analysis could be routinely con-
ducted as part of the critical appraisal process when multi-
ple suitable animal studies are available. Such
meta-analyses would allow more informed decisions as to
which therapeutics might advance to clinical trial.
Alternative pathway case studies: fluid
management in sepsis
As one case study exemplifying the proposed alternative
pathway for preclinical research, a response to a RFP in the
area of fluid management using colloids might characterize
the proposed research as follows. First, the goal of this
research is to determine if colloid therapy of sepsis amelio-
rates organ dysfunction, when administered in volumes that
do not overwhelm the intravascular space. Second, while
mortality is an important outcome for clinical trials of sepsis,
organ dysfunction in animal models is an adequate surro-
gate. Finally, results from this study are to provide informa-
tion for justification and design of clinical trials.
The proposal might then detail a set of hypotheses to be
tested with use of two complementary animal models. It
might, for instance, be hypothesized that colloid therapy
will: (1) retard the progression of sepsis in sheep, as
judged by reduction in tissue injury and gut translocation of
endotoxin and improved circulatory reserve to a standard-
ized hypoxic insult; (2) inhibit the progression of sepsis in
rats, as evaluated by diminished myocardial, gut and renal
dysfunction; and (3) reduce inflammation of the heart asso-
ciated with sepsis in rats and sheep. Hypotheses (1) and
(2) would be intended to satisfy the requirements of the
RFP. Hypothesis (3) would address a potential mechanism
of colloid action based upon prior evidence, such as the
observation that fluid resuscitation can attenuate cytokine
gene expression in experimental murine peritonitis [29].
The hypotheses, taken together, would both meet the
needs of the RFP sponsor for data to justify and design
clinical trials and address special research interests of the
investigators submitting the proposal.
In evaluating the research proposal, it would be essential
to ask how similar the animal models are to the clinical
condition of interest. In a model of sepsis, for example, to
what extent might the experimental animals conform to the
established criteria for human sepsis? Perhaps fitting two
or more of the following: temperature >38 or <36°C; heart
rate >90 beats/min; respiratory rate >20 breaths/min or
PaCO2 <32 mmHg; and white blood cells >12000 or
<4000 cells/mm3, or >10% immature (band) forms [30]?
Similarly, do the responses of the experimental animals to
treatment resemble those anticipated in septic patients?
Polymyxin–dextran anti-endotoxin pretreatment in an ovine
model of normotensive sepsis produced an array of
responses similar to those expected in patients, as shown
in Table 3 [31]. This model would thus satisfy at least
some of the criteria for appropriate preclinical evaluation
of sepsis therapies.
The rigorousness of the study design would serve as
another key criterion for evaluating the quality of the pro-
posed research. The already described ovine model study
was designed to address the hypothesis that, in sheep
with sepsis induced by caecal ligation and perforation,
pretreatment with polymyxin–dextran anti-endotoxin would
be associated with fewer changes in microvascular
integrity and cellular architecture in extrapulmonary organs
[31]. The study was, importantly, a prospective double-
blind, randomized trial, thus clearly conforming to the
design requirements for definitive clinical trials.
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Table 2
Methodology of meta-analysis
Protocol development
Definition of population, intervention and outcomes
Specification of data sources and selection criteria
Search strategy
Adequate comprehensiveness
Sources and techniques
Language restrictions
Study selection
A priori criteria
Justification of exclusions
Methodologic quality assessment
Basis for inclusion, explanation of heterogeneity or sensitivity 
analyses
Minimization of bias
Quality scoring system
Data extraction
Specification of data to be extracted
Avoidance of bias
Inclusion of all relevant data
Analysis
Appropriate model (fixed versus random effects)
Effect size (eg relative risk, odds ratio, risk difference)
Precision (confidence intervals)
Evaluation of heterogeneity
Subgroup analyses
Sensitivity analysesThe ovine model of sepsis has also been used to compare
resuscitation fluids. This blinded study tested the hypothe-
sis that type of fluid infused will modify both microvascular
integrity and cellular structure in sepsis [32]. Sheep were
randomized to receive crystalloid (Ringer’s lactate) or
colloid (pentastarch) for 48 h beginning 6 h after induction
of experimental sepsis. Fluid was infused to maintain con-
stant left atrial pressure. In order to maintain similar plasma
volumes (Figure 2), it was necessary to infuse a signifi-
cantly greater volume of crystalloid than colloid. Higher
colloid osmotic pressure was achieved in the colloid recip-
ients (Figure 2). These observations in the ovine model are
consistent with those expected in patients. Moreover, fluid
was titrated to achieve a target end diastolic filling pres-
sure, and this mode of administration is typical of the fluid
management approach taken in the clinical setting. The
data in Figure 2 also reveal that the randomized groups
were comparable in baseline plasma volume and colloid
osmotic pressure. Demonstration of the comparability of
the study groups at baseline is also important in random-
ized clinical trials. While both groups attained a similar
hyperdynamic circulatory response, the pentastarch group
exhibited greater capillary luminal areas with less endothe-
lial swelling and less parenchymal injury. This blinded ran-
domized trial in an animal model thus provided evidence of
benefit with a colloid used in a manner similar to that
employed in patients.
Another case study involving blood or blood-substitute
preparations demonstrates the application of animal
studies in elucidating underlying physiologic mechanisms
of clinical relevance. It has been shown that transfusion of
older blood was associated with evidence of gastric
mucosal ischaemia in septic patients [33]. Red cell trans-
fusion was also found ineffective for increasing splanchnic
tissue oxygen utilization in septic patients as measured by
gastric pHi [34]. These observations suggested that the
age of transfused blood might be an important determi-
nant of tissue oxygenation, and this possibility was
assessed in a rodent model. Storage of rat red blood cells
in this prospective randomized trial for 28 days impaired
the ability to improve tissue oxygenation when transfused
into either control or septic rats in a state of systemic
oxygen uptake (VO2) supply dependency induced by iso-
volaemic haemodilution [35]. Similar observations have
subsequently also been made in an ovine model.
The impaired oxygenation associated with stored blood
may be a temporary phenomenon, since these blood cells
may eventually undergo rejuvenation. Intravital video
microscopy observations have indicated the occurrence of
capillary dropout after transfusion of stored blood. Such
dropout might be due to the increased rigidity of the
stored cells, as well as, possibly, increased adhesion to
endothelium. It is clear, in any case, that rigorously
designed animal studies can have an important role to play
in deducing physiologic mechanisms relevant to clinical
fluid management.
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Figure 2
Effects of fluids in an ovine model of sepsis. (a) Plasma volume and 
(b) plasma osmotic pressure at baseline and 48 h in sheep with
experimental sepsis receiving either pentastarch (black bars) or
Ringer’s lactate (white bars). Based on the data of Morisaki et al [32].
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Table 3
Results of anti-endotoxin pretreatment in an ovine model of
normotensive sepsis* [31]
Less pyrexia (P = 0.04)
Higher mean arterial pressures (P = 0.02)
Less variable serum albumin concentration (P = 0.05)
Trend toward decreased lactate concentration (P = 0.10)
*48 h after randomizationCritical Care    Vol 4 No S2 Sibbald
Conclusion
The fluid management landscape has been altered by
recent meta-analyses, whatever their methodological limi-
tations may have been. Yet important questions regarding
optimal fluid management remain unanswered, and more
research is needed. Experimental models that mimic, as
faithfully as possible, a clinical condition of interest can
make an important contribution. An alternative pathway of
preclinical research might serve to reduce the risks and
costs of developing therapies, thereby benefiting all partic-
ipants in the healthcare system. Key elements of this
pathway consist of hypotheses specified by developers of
therapeutics, a competitive research process, randomized
studies in clinically relevant animal models and critical
appraisal, possibly including meta-analysis of animal data.
Commentary
Jean-Louis Vincent, MD, PhD: Are not the data already
reported on albumin administration in preclinical models
sufficient? Much evidence has accumulated from the
experimental studies of colloids as compared with crystal-
loids. What are the animal studies remaining to be done?
William J Sibbald, MD: That question can only be
answered when framed very specifically in terms of the
clinical condition of interest and the intended therapeutic
intervention. In this context, it is not at all clear that all the
relevant studies have already been performed.
Andrew R Webb, MD: Also, the quality of the available
data should be considered. Much of what has been
reported regarding colloids and crystalloids cannot be
readily interpreted in terms of implications for clinical prac-
tice.
Jean-Louis Vincent, MD, PhD: Are there not also impor-
tant limitations to the clinical questions that can be mean-
ingfully addressed in animal models? For example, models
of multiple organ failure are difficult to devise. Also, adult
respiratory distress syndrome cannot easily be repro-
duced in animals.
William J Sibbald, MD: While there may be some limitations,
the versatility of animal models in mimicking a broad range of
clinical conditions should nevertheless be recognized.
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